- THRIVE and THRIVE-2 clinical trials are continuing to enroll active and chronic thyroid eye disease (TED) patients; expected delivery of topline clinical results for both clinical trials on track for 2024 -- Timing for the selection of lead subcutaneous TED program is on track for the end of 2023 -- Advancing rece...
Related Keywords
Waltham ,Massachusetts ,United States ,Steve Mahoney ,Shan Wu ,Viridian Therapeutics Inc ,Nasdaq ,Neither The Company ,Exchange Commission ,Stephen Mahoney ,Chief Executive Officer ,Viridian Therapeutics ,Generation Fcrn Portfolio ,Thomas Beetham ,Chief Operating Officer ,Chief Business ,Private Securities Litigation Reform Act ,Thyroid Eye Disease ,Quarterly Report ,
comparemela.com © 2020. All Rights Reserved.